This Is MS Multiple Sclerosis Knowledge & Support Community

Is it time to give Campauth a second look? If you were just wanting to stop progression? How does 65% compare to HSCT?

Results of the five-year review showed:

an estimated 65 percent of alemtuzumab-treated patients were free of clinically-active disease, compared to 27 percent of patients taking Rebif (p<0.0001). To be free of clinically-active disease, MS patients in the trial were both relapse-free and without a sustained increase in disability as measured by the Expanded Disability Status Scale (EDSS) through five years;

an estimated 72 percent of alemtuzumab-treated patients were relapse-free compared to 41 percent of patients taking Rebif; and

an estimated 87 percent of alemtuzumab-treated patients were free of sustained accumulation of disability compared to 62 percent of patients taking Rebif (previously reported).

Looking88 wrote:Is it time to give Campauth a second look? If you were just wanting to stop progression? How does 65% compare to HSCT?

Results of the five-year review showed:

an estimated 65 percent of alemtuzumab-treated patients were free of clinically-active disease, compared to 27 percent of patients taking Rebif (p<0.0001). To be free of clinically-active disease, MS patients in the trial were both relapse-free and without a sustained increase in disability as measured by the Expanded Disability Status Scale (EDSS) through five years;

an estimated 72 percent of alemtuzumab-treated patients were relapse-free compared to 41 percent of patients taking Rebif; and

an estimated 87 percent of alemtuzumab-treated patients were free of sustained accumulation of disability compared to 62 percent of patients taking Rebif (previously reported).

Hi Looking 88,

No doubt Campath is a good drug. Much better than the CRAB agents. I wish it had been available when I was diagnosed in 1996.

If one just wants to "stop" the underlying MS disease activity & progression, here's how HSCT performs (based on the clinical trials completed to date) based on disease status at time of treatment (number shown here is based upon the number of people from the total MS population, not the percentage of measured improvement in any given individual which is all over the map):

Early RRMS = 100% stopping of disease activity
Advanced SPMS = 79% stopping of disease activity
Advanced PPMS = 66% stopping of disease activity

I graphed it out on a single page here. . . .

<shortened url>

And then comparing Campath with HSCT curative efficacy, here's what Dr. Richard Burt had to say relative this subject. . . .


.